Apollo Hospitals Q2 FY27 Results: Revenue up 23%, PAT up 32%
Apollo Hospitals reported Q2 FY27 results with consolidated revenue up 23% to ₹76,149 million and PAT up 32% to ₹6,301 million. For H1 FY27, revenue grew 22% to ₹145,468 million and PAT rose 33% to ₹12,106 million. AHLL completed a stake transfer for ₹1,550 crore on October 12, 2026.
The announcement details significant financial performance improvements and a major corporate transaction (stake transfer), which are material events for investors and stakeholders.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT across consolidated and segment-wise performances, indicating positive financial health and operational efficiency.
Apollo Hospitals Enterprise Limited has announced its financial results for the three and six months ended September 30, 2026. The company reported a consolidated revenue growth of 23% to ₹76,149 million for Q2 FY27, compared to ₹61,888 million in Q2 FY26. Consolidated EBITDA saw a significant increase of 29% to ₹11,910 million, up from ₹9,244 million in the previous year.
Consolidated Profit After Tax (PAT) also demonstrated strong growth, rising by 32% to ₹6,301 million in Q2 FY27, from ₹4,773 million in Q2 FY26. For the half-year ended September 30, 2027 (H1 FY27), consolidated revenue grew by 22% to ₹145,468 million, and consolidated PAT increased by 33% to ₹12,106 million.
The company's Healthcare Services segment reported a revenue growth of 23% in Q2 FY27, driven by a robust increase in volumes and higher complexity clinical work. The Diagnostics & Retail Health (AHLL) segment saw its revenue and EBITDA grow by 20% and 79% year-on-year respectively in Q2 FY27, primarily fueled by a 24% YoY growth in Diagnostics. The Digital Health & Pharmacy Distribution segment (Apollo HealthCo) reported a revenue growth of 23% in Q2 FY27, with its EBITDA growing by 75% year-on-year.
Notably, AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026, for a total consideration of ₹1,550 crore. This transaction has led to these businesses being classified as discontinued operations.
What to do with a filing like this
Apollo Hospitals Enterprise Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Apollo Hospitals Enterprise Limited. Read the original for the full detail.